# To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

Source: https://onco.cc/trials/nct07368998/  
OnCo record `nct07368998` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Inavolisib and Fulvestrant in advanced solid tumours, run by Hoffmann-La Roche, now recruiting.

## Summary

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer is a phase 2 interventional study registered as NCT07368998 by Hoffmann-La Roche, with 80 participants planned, started 2026-02-18 and due to reach its primary completion in 2028-10-31. Interventions recorded: Inavolisib and Fulvestrant.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07368998
- Phase: 2
- Setting: A Phase II, Randomized, Open-Label Study Evaluating Two Inavolisib Dose Levels in Combination With Fulvestrant in Participants With PIK3CA-Mutated, HR-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
- Sponsor: Hoffmann-La Roche
- Enrolled: 80

## Sources

- ClinicalTrials.gov NCT07368998: https://clinicaltrials.gov/study/NCT07368998

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Fulvestrant](https://onco.cc/drugs/fulvestrant/), [Inavolisib](https://onco.cc/drugs/inavolisib/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct07368998.json